| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8109918 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(5 months from now) | |
| US7951131 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(5 months from now) | |
| US7951130 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(5 months from now) | |
| US7662141 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(5 months from now) | |
| US7713255 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(5 months from now) | |
| US7951133 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(5 months from now) | |
| US9585681 | INTERSECT ENT INC | Device and methods for treating paranasal sinus conditions |
Apr, 2026
(2 years from now) | |
| US7544192 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Nov, 2026
(3 years from now) | |
| US8025635 | INTERSECT ENT INC | Device and methods for treating paranasal sinus conditions |
Jun, 2027
(3 years from now) | |
| US10357640 | INTERSECT ENT INC | Expandable devices and methods for treating a nasal or sinus condition |
Oct, 2031
(8 years from now) | |
| US8763222 | INTERSECT ENT INC | Methods and devices for crimping self-expanding devices |
Feb, 2032
(8 years from now) | |
| US10406332 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Mar, 2034
(10 years from now) | |
| US10232152 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Nov, 2034
(11 years from now) | |
Sinuva is owned by Intersect Ent Inc.
Sinuva contains Mometasone Furoate.
Sinuva has a total of 13 drug patents out of which 0 drug patents have expired.
Sinuva was authorised for market use on 08 December, 2017.
Sinuva is available in implant;implantation dosage forms.
Sinuva can be used as treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant.
The generics of Sinuva are possible to be released after 24 November, 2034.
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT;IMPLANTATION
SINUVA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic